LNTH
Lantheus Holdings, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$101.08
+0.28%Year over year
Reported trailing growth
- Revenue
- +2.3%
- EBITDA
- +3.1%
- EBIT
- -30.9%
- EPS
- +7.1%
- Free cash flow
- -17.6%
- Operating cash flow
- -21.4%
Forward estimates
Based on analyst estimates
- Revenue
- +1.9%
- EBITDA
- +23.9%
- EPS
- +42.7%
Three-year CAGR
- Revenue
- +18.1%
- EBITDA
- +70.2%
- EBIT
- +104.8%
- Net income
- +102.6%
- EPS
- +103.6%
- Free cash flow
- +10.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026